argenx SE (NASDAQ:ARGX) Shares Purchased by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. boosted its position in shares of argenx SE (NASDAQ:ARGX) by 215.8% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 110,390 shares of the company’s stock after acquiring an additional 75,435 shares during the quarter. Assenagon Asset Management S.A. owned 0.18% of argenx worth $65,336,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. FMR LLC boosted its stake in shares of argenx by 17.2% in the fourth quarter. FMR LLC now owns 5,618,222 shares of the company’s stock valued at $3,455,207,000 after purchasing an additional 824,750 shares during the period. Point72 Asset Management L.P. acquired a new stake in argenx during the 4th quarter worth approximately $91,013,000. Allspring Global Investments Holdings LLC boosted its position in argenx by 38,152.3% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 144,211 shares of the company’s stock valued at $89,391,000 after buying an additional 143,834 shares during the period. GAMMA Investing LLC grew its stake in shares of argenx by 53,684.9% in the first quarter. GAMMA Investing LLC now owns 135,538 shares of the company’s stock worth $802,200,000 after acquiring an additional 135,286 shares in the last quarter. Finally, Marshall Wace LLP grew its stake in shares of argenx by 184.7% in the fourth quarter. Marshall Wace LLP now owns 191,553 shares of the company’s stock worth $117,805,000 after acquiring an additional 124,271 shares in the last quarter. 60.32% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft upgraded argenx from a “sell” rating to a “hold” rating in a research note on Wednesday, March 12th. Guggenheim reduced their price target on argenx from $1,100.00 to $1,065.00 and set a “buy” rating on the stock in a research report on Friday, May 9th. Wells Fargo & Company lifted their price objective on argenx from $723.00 to $741.00 and gave the company an “overweight” rating in a research note on Friday, February 28th. Wedbush reissued an “outperform” rating and set a $715.00 price objective on shares of argenx in a research report on Wednesday. Finally, HC Wainwright restated a “buy” rating and set a $720.00 target price on shares of argenx in a research note on Tuesday. One analyst has rated the stock with a hold rating, nineteen have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $709.18.

argenx Price Performance

Shares of ARGX opened at $574.96 on Thursday. argenx SE has a 1-year low of $376.59 and a 1-year high of $678.21. The stock has a market cap of $35.11 billion, a PE ratio of -653.36 and a beta of 0.39. The firm has a fifty day moving average price of $586.20 and a 200 day moving average price of $611.99.

argenx (NASDAQ:ARGX) last posted its earnings results on Thursday, May 8th. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.32 by $0.26. The business had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $748.34 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. As a group, equities analysts expect that argenx SE will post 3.13 EPS for the current fiscal year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.